Joseph C Papa bought $350k of EBS
President and CEO at Emergent BioSolutions Inc.. 60,000 shares at an average of $5.83, traded May 13, 2025, filed May 15, 2025.
Score components
- +25RoleCEO
- +15Trade size$350k at market
- +6Relative to holdingsHoldings up 21%
- +8Price context51% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001367644-25-000127, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 13, 2025 | POpen-market purchase Common Stock | +60,000 | $5.83 | $350k | 342,500 | May 15, 2025 |
Related signals
Other insiders at Emergent BioSolutions Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $126k 17,800 shares | -14% | |
| 3Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $20k 3,000 shares | -2% | |
| 20Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $188k 17,801 shares | -13% | |
| 12Weak | Emergent BioSolutions Inc. | Sujata Tyagi Dayal director | $86k 8,552 shares | -9% | |
| 11Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $63k 7,086 shares | -9% | |
| 31Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $68k 7,844 shares | -5% | |
| 2Weak | Emergent BioSolutions Inc. | Keith Katkin director | $49k 7,844 shares | -8% | |
| 35Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $57k 10,000 shares | -18% | |
| 45Moderate | Emergent BioSolutions Inc. | Neal Franklin Fowler director | $204k 35,000 shares | -26% | |
| 41Moderate | Emergent BioSolutions Inc. | Donald W DeGolyer director | $273k 25,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.